Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26700024 | 0.81 | GABRA1 (0.36) | ALDH1A1 | |
| SCHEMBL20314836 | 0.79 | DRD2 (0.32) | MAPT | |
| SCHEMBL24688472 | 0.75 | MAOA (0.39) | KDM4EMAPTRAD52ALDH1A1KMT2A | |
| SCHEMBL16202644 | 0.71 | HPGD (0.38) | KDM4EMAPTALDH1A1GAAADRA2C | |
| SCHEMBL26700013 | 0.71 | TNKS (0.38) | KDM4EMAPTALDH1A1GAAKMT2A | |
| SCHEMBL26700032 | 0.70 | TNKS (0.34) | KDM4EMAPTALDH1A1GAAKMT2A | |
| SCHEMBL3999191 | 0.68 | MAPT (0.44) | KDM4EMAPTRAD52ALDH1A1GAA | |
| SCHEMBL12006585 | 0.68 | MAPT (0.61) | KDM4EMAPTRAD52ALDH1A1GAA | |
| SCHEMBL3923133 | 0.66 | CYP2D6 (0.38) | KDM4EMAPTALDH1A1GAAADRA2C | |
| SCHEMBL13868230 | 0.66 | CYP2D6 (0.38) | KDM4EMAPTALDH1A1GAAADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | KDM4E 3415/4885MAPT 1294/4885RAD52 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.